Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen ...

Shares of TG Therapeutics TGTX were up 5.9% yesterday after the company announced positive top-line data from a phase I study ...

Primary objectives involve assessing the tolerability, pharmacokinetics and safety of VK3019.

New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) ...

It’s looking like Roche may not receive an on-time FDA decision for the subcutaneous version of its cancer immunotherapy Tecentriq. The FDA was supposed to dole out a verdict on subcutaneous Tecentriq ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

Sanofi's subcutaneous formulation of multiple myeloma drug Sarclisa has been approved in the UK, which will be the first market for the on-body injector (OBI) version of the drug.

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myelomaApproval based on multiple studies, including the ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

Immunotherapy, exemplified by Opdivo, enhances cancer treatment by targeting malignant cells using the immune system, offering a more precise approach than traditional therapies. The FDA approved ...

Subcutaneous fat is the outermost layer of fat stored directly beneath your skin. It acts as an energy reserve and provides insulation, but excessive amounts can make you feel uncomfortable or ...